Marengo Therapeutics Partners with Gilead to Conduct Clinical Trial of Invikafusp alfa Plus Trodelvy for Metastatic TNBC and Breast Cancers
Shots:
- Marengo & Gilead have entered into a clinical study collaboration and supply agreement to conduct a P-I/II (START-002) clinical study assessing the safety, tolerability & preliminary efficacy of Invikafusp alfa + Trodelvy to treat metastatic TNBC or metastatic HR+/HER2- breast cancer
- As per the agreement, Gilead will provide Trodelvy while Marengo will sponsor the combination study. Both companies will keep the development and commercial rights to their respective compounds
- Invikafusp alfa alone has shown activity in PD-1 resistant cancers in the ongoing P-I/II (START-001) assessing its safety, tolerability & preliminary activity in biomarker-selected patients with advanced solid tumors
Ref: PR Newswire | Image: Marengo Therapeutics & Gilead
Related News: Ipsen Collaborated with Marengo Therapeutics to Advance Two Precision Immuno-Oncology Therapies Using STAR Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
